{"filing":{"accession_number":"0001437749-26-022876","cik":"0000072444","ticker":"VXRT","company_name":"Vaxart, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"vxrt20260706_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/vxrt20260706_8k.htm"},"events":[{"id":16313,"run_id":14563,"accession_number":"0001437749-26-022876","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vaxart announced topline 12-month safety data from a Phase 2b clinical trial of its oral COVID-19 vaccine candidate, showing no vaccine-related serious adverse events or sustained Grade 3+ adverse events in either arm. This is a material clinical milestone for a clinical-stage biotech company, but it does not fit the specific categories of earnings_release (no financial results), material_litigation, or other named event types. The disclosure represents a significant operational/clinical development that would affect investor assessment of the company's vaccine program progress.","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14378,"accession_number":"0001437749-26-022876","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vaxart announced topline 12-month safety data from a Phase 2b clinical trial of its oral COVID-19 vaccine candidate, showing no vaccine-related serious adverse events or sustained Grade 3+ adverse events in either arm. This is a material clinical milestone for a clinical-stage biotech company, but it does not fit the specific categories of earnings_release (no financial results), material_litigation, or other named event types. The disclosure represents a significant operational/clinical development that would affect investor assessment of the company's vaccine program progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:11:44.195173+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14378,"accession_number":"0001437749-26-022876","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vaxart announced topline 12-month safety data from a Phase 2b clinical trial of its oral COVID-19 vaccine candidate, showing no vaccine-related serious adverse events or sustained Grade 3+ adverse events in either arm. This is a material clinical milestone for a clinical-stage biotech company, but it does not fit the specific categories of earnings_release (no financial results), material_litigation, or other named event types. The disclosure represents a significant operational/clinical development that would affect investor assessment of the company's vaccine program progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:11:44.195173+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-07-07"}]}